NeuroMetrix, Inc. announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription wearable neurotherapeutics business in the U.S. market. The Company recently received FDA De Novo authorization to market its Quell(R) device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.

The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021.Mr. Harmel brings 15 years of experience in high growth medical technology and device sales, including building and managing successful sales teams on a national scale. Mr. Harmel was most recently the U.S.Director of Market Development at Neurolief, which developed and is commercializing a wearable neuromodulation device for migraine. Prior to Neurolief, Mr. Harmel was Regional Director of Business Development for Neuronetics, which markets a transcranial magnetic stimulation (TMS) device for the treatment of major depression.

Before that, he held sales leadership roles at Virgin Pulse, CDx Diagnostics and Avantis Medical Systems.